Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled ‘Real-world Clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan for the Treatment of HER2-positive Metastatic Breast Cancer.’ The study aims to evaluate the real-world outcomes of a specific drug combination in patients with HER2-positive metastatic breast cancer, focusing on metrics such as time to next treatment and overall survival.
The intervention being tested includes a combination of three drugs: Tucatinib, Trastuzumab, and Capecitabine. These drugs are used in a non-interventional, retrospective cohort analysis to assess their effectiveness following Trastuzumab Deruxtecan therapy.
This observational study employs a retrospective time perspective, analyzing de-identified patient data from the Flatiron Health Database. It does not involve any new patient allocation or masking, as it is based on existing records.
The study began on May 7, 2025, with the latest update submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and ensuring the data remains current.
The outcome of this study could influence Pfizer’s stock performance by providing insights into the effectiveness of its drug combination, potentially affecting investor sentiment. It also positions Pfizer competitively within the oncology market, where advancements in treatment options are highly valued.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.